Predicting Toxicity in Elderly Patients With Head and Neck Cancer
ConditionHead and Neck Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age70-99
SponsorEuropean Institute of Oncology
About this trial
Predicting toxicity in elderly patients with head and neck cancer:
validating a disease-oriented toxicity predictive tool and integrating it with avail-able screening tools for better outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged ≥ 70 years
Histological diagnosis of squamous cell or undifferentiated HNC in stage III-IV AJCC ed VIII (si-nonasal, nasopharynx, oral cavity, oropharynx, unknown primary with HPV pos, larynx and hy-popharynx) and candidated to curative non surgical treatment (radiotherapy alone, Chemora-diation with platinum salts; radiation+cetuximab)
Evaluable disease accordingly to RECIST criteria 1.1
Willing of sign a written informed consent
Disqualifiers
PS ECOG 3-4
Patients who received systemic treatments in the past for other primary tumors
Trial population
300 pts from the outpa-tients oncology practice previously discussed at multisciplinary meeting (MD) All the patients with age ≥ 70 years old, diagnosed with HNC candidated to a curative treatment with radiotherapy +/- systemic therapy (chemotherapy or cetuximab) will be evaluated.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Predicting toxicity in elderly patients with head and neck cancer
validating a disease-oriented toxicity predictive tool and integrating it with avail-able screening tools for better outcomes
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov